Belite BioBLTE
Market Cap: $1.48B
About: Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Employees: 20
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
246% more capital invested
Capital invested by funds: $2.46M [Q1] → $8.52M (+$6.06M) [Q2]
0.39% more ownership
Funds ownership: 0.22% [Q1] → 0.61% (+0.39%) [Q2]
0% more funds holding
Funds holding: 11 [Q1] → 11 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Yi Chen 32% 1-year accuracy 44 / 139 met price target | 24%upside $60 | Buy Maintained | 13 Aug 2024 |
Benchmark Bruce Jackson 27% 1-year accuracy 13 / 48 met price target | 18%upside $57 | Buy Reiterated | 13 Aug 2024 |
HC Wainwright & Co. Yi Chen 32% 1-year accuracy 44 / 139 met price target | 22%upside $59 | Buy Reiterated | 13 Jun 2024 |
Financial journalist opinion
Based on 3 articles about BLTE published over the past 30 days